Article
02 October 2025 - by Madeleine Feller, Mackenzie Gill, Kevin Pierce
Despite higher demand for high-cost specialty medications, significant changes in Medicare Part D design have yielded lower out-of-pocket costs for members.
Article
12 May 2025 - by Kevin Pierce, Madeleine Feller, Julia M. Friedman
Insurers of Medicare Advantage and Part D have cited significant financial headwinds, so we dive deeper into their financial statements for insights and trends.
Video
29 January 2025 - by Jessica Naber, Kevin Pierce, Rebecca Smith
Discover how Milliman experts leverage data to help clients unlock new opportunities and drive strategic success.
Article
05 June 2023 - by Kevin Pierce, Jeremy Siborg, Nicole Synnott
Modeling shows directing insurers to maximize use of manufacturer rebates for prescription drug coverage leads to premium increases and lower actuarial values.
Video
19 April 2023 - by Kevin Pierce, Philip Nelson, Alex Cires, Sam Shellabarger
Join our presenters Kevin Pierce, Alex Cires, and Philip Nelson as they highlight some of the hot topics for Medicare Part C and D bid development in advance of the 2024 bid deadline.
Article
18 January 2023 - by Rebecca Gergen, Zeb Leciejewski, David Koenig, Kevin Pierce
Medicare Part D plan sponsors need to understand how liabilities will change and evaluate potential strategies due to impact of the Inflation Reduction Act.
Article
30 September 2022 - by AJ Ally, Matt Berman, Michelle (Klein) Robb, Kevin Pierce
Drug manufacturers should take the time now to understand how the Inflation Reduction Act will affect Medicare and carefully plan.
Video
31 August 2022 - by Kevin Pierce, Jake K. Klaisner, Michelle (Klein) Robb, Samantha D’Anna
After more than a year of deliberation, the U.S. Senate and the U.S House of Representatives passed the Inflation Reduction Act of 2022, and it was signed into law by the President on August 16, 2022. What does this mean for healthcare?
Video
10 August 2022 - by David Koenig, Kevin Pierce, Shyam Kolli, Brian Regan
Join our Milliman consultants as they explore Medicare Parts C & D from a financial perspective, highlighting recent financial performance, discussing key CMS files health plans use to monitor financials, considering cash flows including various settlements, and offering insights on risk-based capital considerations.
Article
22 July 2022 - by Michelle (Klein) Robb, Kevin Pierce, Samantha D’Anna, Jake K. Klaisner
We examine key provisions of Senator Schumer and the Senate Finance Committee’s new Prescription Drug Pricing Reform language, and compare with the Build Back Better Act’s previous version.